2016
Gurugram (India)
Series A
Pathkind Labs is a Indian diagnostics sector, offering pathology and laboratory testing services across the country. The company has built a pan-India footprint with over 100 labs and 3,000+ collection centers, serving both urban and deep Tier 2/3/4 markets. The company differentiates itself through a focus on accessibility, affordability, and quality. Its NABL-accredited labs utilize state-of-the-art technology, and Pathkind’s strategy of establishing labs (not just collection centers) in smaller towns ensures rapid, reliable diagnostics for underserved populations.
Comprehensive Diagnostic Testing: Offers 3,500+ tests, including routine blood work, advanced molecular diagnostics, cytogenetics, histopathology, immunoassays, and infectious disease panels.
Preventive Health Packages: Healthkind Packages (Advance, Complete, Active) provide bundled preventive check-ups covering heart, diabetes, liver, kidney, thyroid, and more, with results typically delivered within 24–48 hours.
Specialized Services: National Reference Laboratory for esoteric and high-complexity testing.
Home Collection and Digital Access: Home sample collection and online report delivery, enhancing convenience for patients nationwide.
Fee-for-Service Model: Core revenue is generated from diagnostic test fees paid by individuals, hospitals, and doctors. The company’s broad test menu and tiered pricing support both mass-market and specialized segments.
Franchise and Network Expansion: Pathkind operates a franchise model, enabling rapid scale with local partners while maintaining quality and brand standards. Franchisees contribute to revenue through a commission/revenue-sharing structure.
Hospital and Corporate Partnerships: Revenue from hospital lab management contracts and corporate wellness programs, diversifying the client base.
Roche Diagnostics: Partnership to offer advanced diabetes and cardiac care diagnostics, including NTProBNP testing for heart failure risk in diabetes patients.
PlayAblo: Collaboration for staff training and learning management, supporting operational excellence in remote locations.
HROne: HR technology partnership to streamline internal processes and support rapid scaling.
Aggressive expansion into Tier 2/3/4 cities, aiming for true pan-India coverage and deeper rural penetration (reflecting recent market trends).
Investment in automation, digital platforms, and home collection to enhance convenience and operational efficiency.
New partnerships for advanced diagnostics (e.g., cardiac and molecular testing) and expansion of preventive health packages.
Continued franchise network growth to accelerate reach and brand presence.
$25.1 Million
1
$25.1 Million, Series A
as of May 20, 2022
$230 Million
as of May 20, 2022
9.1
as of May 20, 2022
Motilal Oswal
1424
Airmed
N/A
Date | Round Name | Amount | Valuation | Revenue | Revenue Multiple | Investors |
---|---|---|---|---|---|---|
May 20, 2022 | Series A | $25.1 Million | $230 Million | $29.2Million | 7.2x | Motilal Oswal |